Overview
Bernard Sagaert is chief executive officer of etherna, a role he has held since October 2023. He is based in Wavre. Since October 2023 he has also served on the board of directors of the Alliance for mRNA Medicines, and since December 2012 he has been senior consultant life sciences and managing director at Inphacon. He was a board member of Biovia between April 2023 and July 2024.
Sagaert joined etherna in June 2017 as a GMP consultant and went on to hold a succession of roles there, as QA lead, QA/QC lead, vice president and later senior vice president of manufacturing, chief operational officer and interim CEO. From January 2017 to August 2024 he was a qualified person at H.Essers. Earlier he was vice president RA/QA EMEAA at Sterigenics, QA and supply chain director for Belgium at Mylan BVBA - Docpharma BVBA, and held several positions at Docpharma from 2005, including QA and RA director, technical operations director, qualified pharmacist, qualified person for pharmacovigilance and responsible for pharmaceutical information. He was RA manager and then also ICT manager at Purna Pharmaceuticals, and before that RA manager at Farmabel.
Sagaert studied pharmacy at KU Leuven, took a master in administration at the Université catholique de Louvain and completed qualified person and related programmes at the FAGG - AFMPS. He followed the Advanced Management Program at Vlerick Business School in 2022 and 2023.
Career history
In the news
- Alzheimer en dementie roepen vaak veel complexe vragen op, niet alleen over de medische kant, maar ook over wilsbekwaamheid en het levenseinde. 🧠 Op dinsdag 27 oktober 2026 vindt in de Stadsschouwburg Mechelen een unieke en diepgaande lezing plaats: "Alzheimer en dementie: Van preventie tot vragen over het levenseinde." Tijdens deze avond brengen we absolute topexperts samen om inzicht te geven in actuele en maatschappelijke thema's: - Wat is Alzheimer en dementie precies? - Preventie, diagnose en de nieuwste behandelingen.
- Signing this agreement is a defining moment for Etherna, and I could not be prouder of what our team has built with the support of our investors. Over the past years, we have turned a decade of mRNA and LNP expertise into platforms capable of reaching far beyond what conventional mRNA and delivery and manufacturing technologies could ever achieve. Joining forces with Valerio gives that platform the scale, the targeting capabilities and the resources to move faster and further than we could alone. I want to thank our
- Signing this agreement is a defining moment for etherna, and I could not be prouder of what our team has built with the support of our investors. Over the past years, we have turned a decade of mRNA and LNP expertise into platforms capable of reaching far beyond what conventional mRNA and delivery and manufacturing technologies could ever achieve. Joining forces with Valerio gives that platform the scale, the targeting capabilities and the resources to move faster and further than we could alone. I want to thank our
- Looking back to a great etherna #bious in the lovely city of San Diego. Great to see so many existing relations, new ones and old friends. Big steps are being made with our platforms, hearing that early companies again have being able to raise substantial money… I am returning with a good feeling, for David Ricketts it is not over yet, still a full day of meetings ahead! Thank you #biointernational for again a great edition
- Ben je op zoek naar iemand die techniek, creativiteit en structuur weet te combineren? Iemand die technisch sterk is, grafisch kan meedenken én chaos kan omzetten in overzicht? En niet bang is om hard te werken? Simon Etienne is een aanrader!
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.